We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Study Shows Radiotherapy Reduces Risk of Death from Prostate Cancer by Half

By MedImaging International staff writers
Posted on 24 May 2016
Print article
Image: A patient undergoing radiotherapy for prostate cancer (Photo courtesy of Umeå University).
Image: A patient undergoing radiotherapy for prostate cancer (Photo courtesy of Umeå University).
A longitudinal Nordic study has shown that a combination of pill-based hormone therapy and local radiotherapy can halve the risk of death from prostate cancer 15 years after diagnosis.

The results of the study were published in the May 2016 issue of the journal European Urology. The researchers compared the results of treatment using only a standard Nordic pill-based therapy (the hormone antiandrogen) and the same therapy with the addition of local radiotherapy. Treatment using antiandrogens slows down the growth of the cancer cells. A follow-up term of 15 years after diagnosis showed that the treatment that included radiotherapy reduced the risk of patients dying from prostate cancer by half, from 34% to 17%. Approximately 9,000 patients are diagnosed with prostate cancer each year in Sweden.

The Researchers from Umeå University (Umeå, Sweden), and from Norway, and Denmark, followed 875 patients who had been treated for locally advanced prostate, or aggressive prostate cancer between the years 1996 and 2002. The patients were from approximately 40 clinics in Sweden and Norway.

The leader of the study, Anders Widmark, senior physician and professor, Umeå University, said, "When we published the first results of this study in the Lancet in 2009, we contributed to changing the attitude towards radiotherapy for older patients with advanced prostate cancer. In this follow-up study, we present even more evident results that clearly show how patients who previously were considered incurable, to a large extent can be cured and that these patients should therefore be offered radiotherapy as an additional treatment. We are also in the process of evaluating how hormone therapy against prostate cancer affects the patients' quality of life. We will publish that study shortly."

Related Links:
Umeå University

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Portable X-Ray Unit
AJEX240H
New
Wireless Handheld Ultrasound System
TE Air
Ultrasound System
P25 Elite

Print article

Channels

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The Cinematic Reality app enables interaction with realistic renderings of human anatomy (Photo courtesy of Siemens)

AR Application Turns Medical Scans Into Holograms for Assistance in Surgical Planning

Siemens Healthineers (Erlangen, Germany) has launched an app designed for Apple Vision Pro that allows users including surgeons, medical students, or patients to view immersive, interactive holograms of... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.